Raymond James Financial Services Advisors, Inc. Adverum Biotechnologies, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$3.36 - $10.56 $138,542 - $435,420	-41,233 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$9.26 - $14.36 $94,572 - $146,658	10,213 Added 32.92%	41,233 $407,000
Q4 2020 Feb 12, 2021	BUY	$9.84 - $14.26 $305,236 - $442,345	31,020 New	31,020 $336,000
Q3 2020 Nov 04, 2020	SELL	$10.3 - $21.64 $103,803 - $218,087	-10,078 Closed	0 $0
Q2 2020 Jul 17, 2020	BUY	$8.53 - $25.64 $85,965 - $258,399	10,078 New	10,078 $210,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account